|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.74 HKD | -1.24% |
|
-3.78% | -56.96% |
Jan 4 (Reuters) - WuXi Biologics (Cayman) Inc:
* WUXI BIOLOGICS AND GSK ENTER INTO LICENSE AGREEMENT ON MULTIPLE NOVEL BI- & MULTI-SPECIFIC T CELL ENGAGERS
* WUXI BIOLOGICS - WILL RECEIVE AN UPFRONT PAYMENT OF $40 MILLION AND TIERED ROYALTIES ON NET SALES
* WUXI BIOLOGICS- WILL PROVIDE AN EXCLUSIVE LICENSE TO GSK FOR ONE PRECLINICAL BI-SPECIFIC ANTIBODY AND OPTION OF 3 ADDITIONAL BI-/MULTI-SPECIFIC TCE ANTIBODIES Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,640 GBX | +0.28% | +3.60% | 83.1B | ||
| 12.74 HKD | -1.24% | -3.78% | 6.86B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -56.96% | 6.86B | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
WUXI BIOLOGICS (CAYMAN) INC. 
